260 related articles for article (PubMed ID: 22710917)
1. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
Zetterberg H; Blennow K
J Alzheimers Dis; 2013; 33 Suppl 1():S361-9. PubMed ID: 22710917
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.
Schipke CG; Prokop S; Heppner FL; Heuser I; Peters O
Dement Geriatr Cogn Disord; 2011; 31(2):139-45. PubMed ID: 21304219
[TBL] [Abstract][Full Text] [Related]
5. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
Shoji M
Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
[TBL] [Abstract][Full Text] [Related]
6. [A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].
Molinuevo JL; Gispert JD; Pujol J; Rojas S; Lladó A; Balasa M; Antonell A; Sánchez-Valle R; Rami L
Rev Neurol; 2012 May; 54(9):513-22. PubMed ID: 22532214
[TBL] [Abstract][Full Text] [Related]
7. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
Engelborghs S; Le Bastard N
J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
[TBL] [Abstract][Full Text] [Related]
8. [The role of CSF markers in the early diagnosis of Alzheimer's disease].
Vos SJ; Visser PJ; Verhey FR
Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
Galasko D
J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
[TBL] [Abstract][Full Text] [Related]
11. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's CSF markers in older schizophrenia patients.
Frisoni GB; Prestia A; Geroldi C; Adorni A; Ghidoni R; Amicucci G; Bonetti M; Soricelli A; Rasser PE; Thompson PM; Giannakopoulos P
Int J Geriatr Psychiatry; 2011 Jun; 26(6):640-8. PubMed ID: 20872913
[TBL] [Abstract][Full Text] [Related]
13. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
[TBL] [Abstract][Full Text] [Related]
14. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
Wallin AK; Blennow K; Andreasen N; Minthon L
Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease.
Zetterberg H; Lunn MP; Herukka SK
Biomark Med; 2012 Aug; 6(4):371-6. PubMed ID: 22917139
[TBL] [Abstract][Full Text] [Related]
16. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
17. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).
Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J
Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854
[TBL] [Abstract][Full Text] [Related]
18. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
Koric L; Felician O; Guedj E; Hubert AM; Mancini J; Boucraut J; Ceccaldi M
Alzheimer Dis Assoc Disord; 2010; 24(3):278-83. PubMed ID: 20473135
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
[TBL] [Abstract][Full Text] [Related]
20. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C
Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
